Advertisement
Document › Details
Sanofi S.A.. (7/26/18). "Press Release: Sanofi Head of Human Resources Roberto Pucci to Retire, Company Names Caroline Luscombe to Take over October 1st". Paris.
Organisation | Sanofi S.A. (Euronext: SAN, Nasdaq: SNY) | |
Group | Sanofi (Group) [since May 2011] | |
Organisation 2 | Syngenta AG | |
Group | Syngenta (Group) | |
Product | pharmaceutical | |
Product 2 | AGRI LIFE SCIENCES | |
Person | Pucci, Roberto (Sanofi 201606–201812 EVP Human Resources RETIRED 12/18) | |
Person 2 | Luscombe, Caroline (Sanofi 201810– Head of Human Resources before LafargeHolcim + Syngenta + GE + Amersham) | |
Roberto Pucci, Head of Human Resources, will retire from Sanofi after more than 9 years of service with the company. He will be succeeded in the post by Caroline Luscombe who joins Sanofi on October 1st 2018. Mr. Pucci will be available to Ms. Luscombe until the end of the year to ensure a smooth transition.
Mr. Pucci joined Sanofi in 2009 as Executive Vice President and Head of Human Resources, and has substantially transformed the human resources function and supported Sanofi through a period that saw considerable change in the company.
“Roberto has been an excellent partner in our journey to reshape the organization to align with Sanofi’s evolving business ambitions and a great coach to our team and I wish him all the best in his future”, said Sanofi Chief Executive Officer Olivier Brandicourt, M.D.
Appointment of Caroline Luscombe
Ms. Luscombe will report directly to Dr. Brandicourt and will be a member of the Executive Committee.
“Caroline is a seasoned HR leader who will bring tremendous experience and expertise to Sanofi having worked in various industries and across multiple geographies,” said Dr. Brandicourt. “Continuing with the high standards set by Roberto, Caroline will drive the focus on our human capital that is needed in a company of our scope”.
Ms. Luscombe was most recently Head of Organization and Human Resources and member of the Executive Committee at LafargeHolcim, based in Zurich, Switzerland. Before joining LafargeHolcim Ms. Luscombe has been for 6 years the Global Head of Human Resources of Syngenta. She previously held a number of senior HR positions at General Electric (GE) in GE Capital Global Banking, GE Money and GE Healthcare Bio-Sciences. Before its acquisition by GE, she has been Executive Vice President HR for Medical Diagnostics, Amersham plc.
Ms. Luscombe, who started her career in finance at Arthur Young McClelland Moore and was UK controller and Compensation and Benefits manager for the strategy consultants Bain & Company, holds a bachelor’s degree in German from University College, London.
About Sanofi
Sanofi is dedicated to supporting people through their health challenges. We are a global biopharmaceutical company focused on human health. We prevent illness with vaccines, provide innovative treatments to fight pain and ease suffering. We stand by the few who suffer from rare diseases and the millions with long-term chronic conditions.
With more than 100,000 people in 100 countries, Sanofi is transforming scientific innovation into healthcare solutions around the globe.
Sanofi, Empowering Life
Media Relations Contacts
Jack Cox
Tel.: +33 (0)1 53 77 46 46
mr@sanofi.com
Investor Relations Contact
George Grofik
Tel.: +33 (0)1 53 77 45 45
ir@sanofi.com
Record changed: 2023-06-05 |
Advertisement
More documents for Sanofi (Group) [since May 2011]
- [1] GenSight Biologics S.A.. (12/22/23). "Press Release: GenSight Biologics Appoints Laurence Rodriguez as Chief Executive Officer". Paris....
- [2] Sanofi S.A.. (12/11/23). "Press Release: Statement on FTC Challenge to Proposed License Agreement with Maze Therapeutics". Paris....
- [3] Aqemia S.A.S.. (12/5/23). "Press Release: Aqemia Announces a Major Multi-year Collaboration of $140 Million with Sanofi". Paris....
- [4] Eligo Bioscience S.A.. (12/5/23). "Press Release: Eligo Bioscience Raises $30 Million To Write a Novel Chapter for Genetic Medicines". Paris....
- [5] MeiraGTx Holdings plc. (10/30/23). "Press Release: MeiraGTx Announces $30 Million Strategic Investment from Sanofi; Company Pursuing Multiple Additional Strategic Opportunities". London & New York, NY....
- [6] Sanofi S.A.. (10/3/23). "Press Release: Sanofi Announces Agreement for Potential First-in-Class Vaccine against Extraintestinal Pathogenic E. coli". Paris....
- [7] Sanofi S.A.. (3/13/23). "Press Release: Sanofi to Acquire Provention Bio, Adding to Portfolio TZIELD, the First Disease-modifying Treatment for the Delay of Stage 3 Type 1 Diabetes (T1D)". Paris & Red Bank, NJ....
- [8] Avilar Therapeutics, Inc.. (2/16/23). "Press Release: Avilar Therapeutics Increases Financing to $75 Million to Advance Pipeline of Novel Extracellular Protein Degraders". Waltham, MA....
- [9] Sanofi S.A.. (1/11/23). "Press Release: Sanofi Ventures Announces Multi-year Capital Commitment from Sanofi, Increasing Evergreen Fund to $750M". Paris....
- [10] CureVac N.V.. (1/10/23). "Press Release: CureVac Appoints Alexander Zehnder as CEO from April 1, 2023". Mainz & London....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«
Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]
Advertisement
» top